CONSTITUTIVELY ACTIVE SEROTONIIN RECEPTORS
组成型活性血清素受体
基本信息
- 批准号:2675594
- 负责人:
- 金额:$ 23.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-07-01 至 2000-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The mechanism-of-action of clozapine, the prototypical atypical
anti-psychotic drug, has been the subject of intense research aimed
at revealing the key property of this drug that allows it to have
superior antipsychotic activity relative to the more classical
antipsychotic drugs. Evidence indicates that clozapine's high
affinity interactions with the 5HT-2A receptor may be a key factor.
In addition, clozapine has high affinity for the 5HT-2C, 5HT-6, and
5HT-7 receptors. Until recently it has been assumed that
clozapine is a classical competitive antagonist at the 5HT-2A
receptor. However, preliminary data in this proposal reveal that
clozapine is an inverse agonist at the constitutively activated form
of the 5HT-2A receptor, created by site-specific mutagenesis. In
order to explore the possibility that clozapine's atypical activity
may be related to its inverse agonist activity at the 5HT-2A
receptor, the effects of a group of typical and atypical antipsychotic
drugs on the constitutively activated 5HT-2A receptor will be
determined. It is anticipated that if 5HT-2A inverse agonist
activity is a critical factor in atypical drug properties, a correlation
will be found between inverse agonist activity and atypical
antipsychotic activity. In order to ascertain the specificity of the
inverse agonist activity of clozapine at the 5HT-2A receptor, the
effects of clozapine and other atypical antipsychotic drugs at
constitutively activated forms of the 5HT-2C, 5HT-6 and 5HT-7
receptors will be determined. It is anticipated that these studies
should confirm or refute the hypothesis that 5HT-2A receptor
inverse agonist activity is critical to atypical antipsychotic activity,
and may reveal a possible involvement of the 5HT-2C, 5HT-6 or
5HT-7 in atypical drug actions. It is also anticipated that
similarities and differences in the pharmacology of the activated
state of the four 5HT receptors studied will be revealed: this
information may be important in future drug development aimed
at developing inverse agonists for therapeutic purposes.
氯氮平的作用机制,典型的非典型
抗精神病药物,一直是紧张的研究对象,旨在
揭示了这种药物的关键特性,
相对于更经典的抗精神病药物,
抗精神病药物 有证据表明氯氮平的含量很高
与5 HT-2A受体的亲和力相互作用可能是关键因素。
此外,氯氮平对5 HT-2C、5 HT-6和5 HT-2C具有高亲和力。
5 HT-7受体。 直到最近,人们一直认为,
氯氮平是5 HT-2A的经典竞争性拮抗剂,
受体的 然而,该提案中的初步数据显示,
氯氮平是一种组成性激活形式的反向激动剂
5 HT-2A受体,通过位点特异性诱变产生。 在
探讨氯氮平的非典型活性
可能与其对5 HT-2A的反向激动剂活性有关
受体,一组典型和非典型抗精神病药的作用
对组成性激活的5 HT-2A受体的药物将被
测定 预计如果5 HT-2A反向激动剂
活性是非典型药物性质的关键因素,
将在反向激动剂活性和非典型激动剂活性之间发现
抗精神病活性。 为了确定
氯氮平对5 HT-2A受体的反向激动剂活性,
氯氮平和其他非典型抗精神病药物的作用.
5 HT-2C、5 HT-6和5 HT-7的组成型活化形式
将确定受体。 预计这些研究
应该证实或反驳5 HT-2A受体
反向激动剂活性对于非典型抗精神病活性是关键的,
并可能揭示可能涉及的5 HT-2C,5 HT-6或
5 HT-7在非典型药物作用中的作用。 我们还估计到
在药理学的相似性和差异的激活
研究的四种5 HT受体的状态将被揭示:这
这些信息在未来药物开发中可能是重要的,
开发用于治疗目的的反向激动剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Milton Teitler其他文献
Milton Teitler的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Milton Teitler', 18)}}的其他基金
Human 5HT 1E Serotonin Receptor Drug Development (RMI)
人类 5HT 1E 血清素受体药物开发 (RMI)
- 批准号:
7057555 - 财政年份:2005
- 资助金额:
$ 23.06万 - 项目类别:
Molecular Biology of 5HT2A receptor expressing synapses
5HT2A 受体表达突触的分子生物学
- 批准号:
6782269 - 财政年份:2004
- 资助金额:
$ 23.06万 - 项目类别:
Molecular Biology of 5HT2A receptor expressing synapses
5HT2A 受体表达突触的分子生物学
- 批准号:
6869606 - 财政年份:2004
- 资助金额:
$ 23.06万 - 项目类别:
相似海外基金
CHLORPROMAZINE, IMMUNOGENETICS AND TARDIVE DYSKINESIA
氯丙嗪、免疫遗传学和迟发性运动障碍
- 批准号:
3377381 - 财政年份:1984
- 资助金额:
$ 23.06万 - 项目类别:
CHLORPROMAZINE, IMMUNOGENETICS AND TARDIVE DYSKINESIA
氯丙嗪、免疫遗传学和迟发性运动障碍
- 批准号:
3377377 - 财政年份:1984
- 资助金额:
$ 23.06万 - 项目类别:
CHLORPROMAZINE, IMMUNOGENETICS AND TARDIVE DYSKINESIA
氯丙嗪、免疫遗传学和迟发性运动障碍
- 批准号:
3377380 - 财政年份:1984
- 资助金额:
$ 23.06万 - 项目类别:
chlorpromazine によるラット体温変動に及ぼす副腎髄質摘除の影響
肾上腺髓质切除术对氯丙嗪所致大鼠体温波动的影响
- 批准号:
X00210----177078 - 财政年份:1976
- 资助金额:
$ 23.06万 - 项目类别:
Grant-in-Aid for Encouragement of Young Scientists (A)
EFFECTS OF GLUTEN ON PLASMA LEVELS OF CHLORPROMAZINE AND CLINICAL STATE
麸质对氯丙嗪血浆水平和临床状态的影响
- 批准号:
4696658 - 财政年份:
- 资助金额:
$ 23.06万 - 项目类别:
EFFECTS OF GLUTEN ON PLASMA LEVELS OF CHLORPROMAZINE AND CLINICAL STATE
麸质对氯丙嗪血浆水平和临床状态的影响
- 批准号:
3860169 - 财政年份:
- 资助金额:
$ 23.06万 - 项目类别:
CHLORPROMAZINE/BENZTROPINE IN TREATMENT-RESISTANT SCHIZOPHRENIA
氯丙嗪/苯托品治疗难治性精神分裂症
- 批准号:
3945076 - 财政年份:
- 资助金额:
$ 23.06万 - 项目类别:
EFFECTS OF GLUTEN ON PLASMA LEVELS OF CHLORPROMAZINE AND CLINICAL STATE
麸质对氯丙嗪血浆水平和临床状态的影响
- 批准号:
3901133 - 财政年份:
- 资助金额:
$ 23.06万 - 项目类别:
CHLORPROMAZINE/BENZTROPINE IN TREATMENT-RESISTANT SCHIZOPHRENIA
氯丙嗪/苯托品治疗难治性精神分裂症
- 批准号:
3922311 - 财政年份:
- 资助金额:
$ 23.06万 - 项目类别:
CHLORPROMAZINE/BENZTROPINE IN TREATMENT-RESISTANT SCHIZOPHRENIA
氯丙嗪/苯托品治疗难治性精神分裂症
- 批准号:
3860296 - 财政年份:
- 资助金额:
$ 23.06万 - 项目类别: